HighTower Advisors’s AEON Biopharma AEON Stock Holding History

HighTower Advisors’s Portfolio AEON Stock Details AEON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-330	Closed	-$12.8K	–	3733
2024 Q4	$12.8K	Hold	330	–	–	﹤0.01%	3572
2024 Q3	$25K	Buy	+330	New	+$29K	﹤0.01%	3493
2022 Q4	–	Sell	-728	Closed	-$517K	–	3347
2022 Q3	$517K	Hold	728	–	–	﹤0.01%	2000
2022 Q2	$515K	Hold	728	–	–	﹤0.01%	2029
2022 Q1	$513K	Sell	728 -203	-22%	-$142K	﹤0.01%	2153
2021 Q4	$653K	Hold	931	–	–	﹤0.01%	1991
2021 Q3	$653K	Sell	931 -41	-4%	-$28.6K	﹤0.01%	1897
2021 Q2	$677K	Buy	+972	New	+$680K	﹤0.01%	1875

Other funds holding AEON

DIG

Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

DCM

Dupont Capital Management Wilmington, Delaware $2.18M AUM 50.81% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

HighTower Advisors's AEON Position: Q1 2025 in Review

HighTower Advisors sold out of AEON Biopharma (AEON) in Q1 2025, closing a stake of 330 shares — an estimated $12.8K sold.

HighTower Advisors first reported a position in AEON in Q2 2021 and held it in 8 quarters. The position peaked at $677K in Q2 2021. 16 funds tracked by Wall St. Rank hold AEON as of Q1 2025.

HighTower Advisors reported no remaining AEON Biopharma position as of Q1 2025 after selling out during the quarter.
HighTower Advisors sold 330 AEON Biopharma shares in Q1 2025, an estimated $12.8K.
HighTower Advisors first reported a position in AEON Biopharma in Q2 2021 and held it in 8 quarters.
HighTower Advisors's AEON Biopharma position peaked at $677K in Q2 2021.
16 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2025.

Based on HighTower Advisors's 13F filing for Q1 2025, filed 13 May 2025.